BD overall is associated with excess mortality from both natural and unnatural causes. Meta-analytic evidence suggests that all-cause mortality is approximately doubled, with particularly high relative risks for suicide (12-fold) and other unnatural causes (7-fold) alongside a substantial increase in natural-cause deaths (2-fold).9 However, most mortality studies have not separated BD-II from BD-I, leaving BD-II’s specific mortality profile uncertain. Limited data indicate substantial premature mortality in BD-II, for example, an estimated 10- to 20-year reduction in life expectancy,1 with cardiovascular disease a major contributor to natural-cause deaths.10,11 This is likely predicated by shared risk factors and operative biological pathways as well as adverse effects of prescribed agents.12 Unnatural causes, especially suicide, also appear elevated. A large Swedish registry13 reported more frequent suicide attempts in BD-II than BD-I, yet meta-analytic work14 suggests that the risk of suicide death is broadly similar across the 2 subtypes. Many BD-II–focused studies have been underpowered or have not analyzed BD-II separately,11,15–17 rendering conclusions tentative. Whether BD-II differs from BD-I in all-cause or cause-specific mortality remains largely unresolved because direct comparisons are scarce.18
Conclusions and Relevance In this cohort study, BD-II was associated with a significant risk of premature mortality across multiple causes; even after accounting for shared familial factors and relative to BD-I, all-cause mortality remained elevated. These findings underscore the importance of comprehensive psychiatric care for individuals with BD-II.
All-Cause and Cause-Specific Mortality in Patients With Bipolar II Disorder – https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2847398
Bipolar disorder
Bipolar Disorder Linked to Early Death
All-cause mortality was 2.3-fold elevated among women and 2.0-fold higher among men with the psychiatric condition compared with the rest of Sweden after adjusting for other factors, they wrote.
Olanzapine – Think Bipolar and Schizophrenia
Medical News: FDA Okays Generic Version of Zyprexa – in Psychiatry, Schizophrenia from MedPage Today
The FDA has approved a generic version of atypical antipsychotic drug olanzapine (Zyprexa) to treat schizophrenia and bipolar disorder.
According to the AP story:
Drugs like Zyprexa can cost up to $500 per month. Generic versions can cut the cost by up to 80 percent.
This is great news.

Ziprasidone (Geodon) – Think Bipolar
Ziprasidone comes with a long list of precautions and contraindications:
* It should not be used in patients with a known history of QT prolongation, recent acute myocardial infarction, or uncompensated heart failure, and should not be used with other QT-prolonging drugs.
* It should also be avoided in elderly patients with dementia-related psychosis, as studies have shown that ziprasidone increases the risk of death in such patients.
* Discontinuation should be considered in patients showing signs of tardive dyskinesia.
* Treatment should be stopped immediately in patients with symptoms of neuroleptic malignant syndrome, which include hyperpyrexia, muscle rigidity, diaphoresis, tachycardia, irregular pulse or blood pressure, cardiac dysrhythmia, and altered mental status.
* Patients and clinicians should be alert for hyperglycemia, rash, seizures, and orthostatic hypotension with ziprasidone.

Saphris – Think Schizophrenia or Bipolar
I suppose Saphris sounds better than asenapine.
FDA approval was based on data from more than 3,000 patients showing statistically significant efficacy versus placebo in acute schizophrenia trials and statistically significant reduction of bipolar mania symptoms versus placebo.
